Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae.
Mucormycosis is a potentially fatal, rapidly destructive, opportunistic infection often seen in immunocompromsied individuals and patients with diabetes mellitus. We describe two patients with rhino-orbital mucormycosis caused by Rhizopus oryzae who received posaconazole within 7 days of diagnosis and in whom cure was achieved in conjunction with extensive surgical resection of diseased tissue. Posaconazole was well-tolerated. Our experience indicates that this new extended-spectrum azole antifungal agent can be used early in the course of zygomycete infection with good results.
Kok
Jen
J
Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, Sydney, New South Wales, Australia. jenk@icpmr.wsahs.nsw.gov.au <jenk@icpmr.wsahs.nsw.gov.au>
Gilroy
Nicole
N
Halliday
Catriona
C
Lee
Ok Cha
OC
Novakovic
Daniel
D
Kevin
Patrick
P
Chen
Sharon
S
D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D015521:Ethmoid Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D015523:Maxillary Sinusitis / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery; D008875:Middle Aged; D009091:Mucormycosis / Q000188:drug therapy* / Q000601:surgery; D012233:Rhizopus / Q000302:isolation & purification*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole